12 Ha’ilan St. P.O.BOX 174 | Or- Aqiva 3063908 074-7650353 info@almd-solutions.com

Analyst Reports

Making progress across the board

20 August, 2018

Allium has reported H118 financial results. Revenues increased 31% y-o-y to NIS4.9m. As before, we continue to expect additional product approvals during 2018 and sales growth from its distribution deals in new and established markets

Continuing to execute on an ambitious plan

17 July, 2018

Following broad FDA approval for Gardia, Allium anticipates the publication of clinical study results in a leading cardiology journal. Allium believes this will further increase Gardia’s attractiveness for both physicians and potential partners.

Wirion approved by FDA; new stents in Europe

26 April, 2018

Allium has announced FDA approval of its subsidiary Gardia’s Wirion, which has become the only embolic protection system approved for all atherectomy procedures

It is all about business execution

24 December, 2017

Gardia Medical’s Wirion device is on track for FDA submission, expected by end-2017; approval is possible in Q218. If approved, it would become the only embolic protection system for all atherectomy procedures in the legs which we think will help to reach a strategic transaction.

Positive data, H117 results and forecasts update

5 September, 2017

Allium has announced that Gardia Medical’s Wirion device has met the primary endpoint of its clinical trial, an important milestone for strategic partnering discussions.

Business progressing on multiple fronts

23 July, 2017

Allium Medical has made significant progress across business lines. The safety monitoring board has recommended continuing the study of Gardia’s embolic protection device; clinical data will be reported by end Q317.

Growth continues, investment case reinforced

16 March, 2017

Allium Medical Solutions has reported FY16 financial results, which impressed with revenue growth of 42% to NIS7.4m vs NIS5.2m in 2015, in line with our expectations.

Revenues continue to grow in key markets

24 November, 2016

Allium Medical Solutions’ Q316 and 9M16 results are encouraging.
Revenues in Q316 were NIS1.6m, up 46% vs Q315, while 9M16 revenues were NIS5.5m, up 54% vs 9M15.

Fast-growing innovative products player

2 November, 2016

 Allium Medical Solutions boasts a portfolio of products in diverse clinical areas such as urology and cardiovascular, with the majority of revenues derived from urology stents.